The global nutrition company, founded in 1980, sells products including protein shakes, dietary supplements and weight-management solutions, operating in more than 90 markets.
The new randomized clinical trial will involve adults with obesity starting GLP-1 therapy and form part of the wider Peacetime obesity care program. Developed by healthcare professionals, academics and people living with obesity, the program brings multidisciplinary specialist care to 9,000 people across Ireland and Northern Ireland.
Florencia Braga, senior manager of scientific affairs in Europe and Africa at Herbalife, said: “We’re very pleased to have the opportunity to work with Ulster University on what we hope will be an important piece of research.
“While we know that GLP-1s are effective in reducing overall body mass, they are associated with a number of unwanted effects which include insufficient intake of key nutrients and marked loss of muscle mass. We want to understand how nutritional strategies can best support people using these therapies.”
Herbalife has recently expanded its focus on personalized nutrition and health technology through a series of strategic acquisitions and investments.
At the start of this year it acquired assets of UK-based personalized supplement company Bioniq, subsequently launching Bioniq GO across 11 European markets and the US. Herbalife also invested in digital wellness through its Pro2col platform, which tracks health habits and wellness data, and made recent investments in metabolic health supplement advancements.
The impact of GLP-1s
GLP-1 medications mimic naturally occurring satiety hormones, slow gastric emptying and suppress appetite, prompting users to reduce overall food intake and daily calorie consumption by approximately 10% to 30%. In the United States, approximately 11% to 12% of adults now use these medications, while uptake in the UK has reached an estimated 4% to 7%.
The substantial reduction in calorie consumption associated with GLP-1 medications has raised concerns about nutritional deficiencies and physical side effects, creating a rapidly expanding market for companion nutrition products. A reviewpublished in Clinical Obesity found that 12.7% of GLP-1 patients developed a new nutritional deficiency within six months of treatment, with deficiencies particularly affecting vitamin D, iron, calcium, magnesium, potassium and choline.
Research also estimates that lean muscle accounts for approximately 25% to 39% of total weight lost by GLP-1 users. This has driven considerable demand for protein powders, shakes, and bars as consumers seek to maintain muscle mass while reducing body weight.
In response, supplement manufacturers and health brands are increasingly developing targeted formulations to address the nutritional and physical challenges associated with treatment.
Herbalife-funded study
The newly launched research project, funded through the collaboration with Herbalife, will investigate how protein- and micronutrient-enriched shakes could support people with obesity who are receiving GLP-1 weight-loss medication.
The research aims to strengthen understanding of how nutritional strategies can complement GLP-1 therapies, shifting the focus from weight reduction alone towards preserving muscle, maintaining nutritional health and achieving more sustainable weight-loss outcomes, Prof Alex Miras, Peacetime project lead, said.
“Peacetime represents a landmark shift in obesity care at the European level by implementing evidence-based, interdisciplinary care into real-world community settings,” Miras said.
By embedding this Ulster University-led clinical research trial within the Peacetime program, we have a unique opportunity to understand how nutritional strategies can support people receiving GLP-1-based therapies and help ensure that weight loss is achieved in a healthy and sustainable way.”




